Advanced Heart Failure: A Position Statement of the Heart Failure Association of the European Society of Cardiology
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.
Résumé
This article updates the Heart Failure Association of the European Society of Cardiology (ESC) 2007 classification of advanced heart failure and describes new diagnostic and treatment options for these patients. Recognizing the patient with advanced heart failure is critical to facilitate timely referral to advanced heart failure centres. Unplanned visits for heart failure decompensation, malignant arrhythmias, co-morbidities, and the 2016 ESC guidelines criteria for the diagnosis of heart failure with preserved ejection fraction are included in this updated definition. Standard treatment is, by definition, insufficient in these patients. Inotropic therapy may be used as a bridge strategy, but it is only a palliative measure when used on its own, because of the lack of outcomes data. Major progress has occurred with short-term mechanical circulatory support devices for immediate management of cardiogenic shock and long-term mechanical circulatory support for either a bridge to transplantation or as destination therapy. Heart transplantation remains the treatment of choice for patients without contraindications. Some patients will not be candidates for advanced heart failure therapies. For these patients, who are often elderly with multiple co-morbidities, management of advanced heart failure to reduce symptoms and improve quality of life should be emphasized. Robust evidence from prospective studies is lacking for most therapies for advanced heart failure. There is an urgent need to develop evidence-based treatment algorithms to prolong life when possible and in accordance with patient preferences, increase life quality, and reduce the burden of hospitalization in this vulnerable patient population.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- European Journal of Heart Failure
- Thématique
- Mechanical Circulatory Support Devices
- Domaine
- Engineering
- Établissements canadiens
- —
- Organismes subventionnaires
- ServierGlaxoSmithKlineDeutsche ForschungsgemeinschaftAstellas PharmaAbiomedHeartWareEuropean Society of CardiologyVifor PharmaPfizerThoratec CorporationSanofiRespicardiaAbbott VascularSt. Jude MedicalZOLL Medical CorporationAstraZenecaAmgen
- Mots-clés
- MedicineHeart failureCardiogenic shockIntensive care medicineHeart transplantationDecompensationCanadian Cardiovascular SocietyEjection fractionDestination therapyQuality of life (healthcare)PopulationInotropeInternal medicineManagement of heart failureCardiologyMyocardial infarctionAngina
- Résumé présent dans OpenAlex
- oui